PortfolioPortfolio mode

GILD

Gilead Sciencesstock

$156.040.73% today

Trade GILD

← Research only mode

Research GILD

GILD · 90-day price history

Market cap

$194.1B

Div yield

2.10%

Industry

Drug Manufacturers - General

Exchange

NasdaqGS

Website ↗

Prediction models

All predictions →

Trend follower

Horizon: 1 week

Signal strength0.53

Historical accuracy59%

27 predictions · 12mBaseline 63%

How this works

Compares a 10-day vs 50-day moving average. When the short-term average rises above the long-term average, the trend is up.

Not financial advice. Past accuracy does not guarantee future results.

Momentum

Horizon: 1 week

down

Signal strength0.23

Historical accuracy19%

27 predictions · 12mBaseline 63%

How this works

Uses RSI (a gauge of recent buying/selling intensity) and 5-day rate-of-change to judge whether the stock has been pushed too far in one direction.

Not financial advice. Past accuracy does not guarantee future results.

Statistical trend

Horizon: 1 month

Signal strength0.53

Historical accuracy100%

10 predictions · 12mBaseline 92%

How this works

Fits a trend line through the last 60 days of prices and measures how far the current price has strayed from it.

Not financial advice. Past accuracy does not guarantee future results.

Multi-factor + news

Horizon: 1 week

AI + NEWS

Signal strength0.35

Historical accuracy56%

27 predictions · 12mBaseline 63%

Accuracy reflects technical signals only. News sentiment is live.

How this works

Combines trend (25%), momentum (25%), volume (15%), and AI-analysed news sentiment (35%) from your trusted sources into one score.

Not financial advice. Past accuracy does not guarantee future results.

Bull / Bear thesis

AI analysis

Bull case●

Expected to beat Q3 earnings estimates

Analyst consensus shows earnings beat likely

Yahoo

M&A acquisition of IL-23R program expands inflammation pipeline

PepStar acquisition brings new IBD treatment option

Yahoo

New clinical data presentations signal active pipeline development

Liver Meeting presentations show ongoing research progress

Yahoo

Bear case●

Stock down 1.88% despite positive setup

Market skeptical on guidance or valuation

Price action

M&A into competitive IBD space not differentiated

IL-23R is crowded therapeutic category

Price action

Earnings beat already expected so limited upside surprise

Market has already adjusted for positive results

Price action

AI-generated from recent news and price action. Not financial advice. Educational only.

Seasonality

~5y of history

Avg return by month · %

This month historically: +8.58% on average, up 80% of 5 years.

Avg return by weekday · %

Historical pattern only — seasonality is not a prediction and often breaks.

Recent news

Gilead acquires IL-23R program for inflammatory bowel disease

Yahoo · Oct 22

Strategic acquisition strengthens Gilead's inflammation pipeline in IBD market

Gilead presenting clinical data on liver diseases at Liver Meeting

Yahoo · Oct 22

Conference presentations validate Gilead's leadership in viral hepatitis treatments

AI research companion

AI Research Companion

Loading…